|
OVARIAN CANCER COMBINATION THERAPY
Prolanta has also been shown to have an synergistic effect
when used with docetaxel in a mouse xenograft model of ovarian cancer. Both
tumor weight and number of tumor nodules were reduced when Prolanta was added to
docetaxel.
The SKOV3 cell line and a mouse ovarian cancer cell line, ID8, were used to
evaluate the synergistic effects of the combination of Prolanta with a standard
chemotherapy agent, docetaxel (DCT), on tumor growth.
For both experiments, one million cells were injected intraperitoneally on Day
1. Treatment with both agents was
begun on Day 8. Treatment consisted
of 100 µg of Prolanta daily, 25 µg of DCT weekly, or both.
The control group received mannitol buffer only.
Nine to 10 mice were treated in each group.
Mice were treated until moribund (38 days for the SKOV3-injected mice and
52 days for the ID8-injected mice), at which time they were euthanized and their
tumor nodules were counted and weighed.
Terminal body weights were also obtained as a measure of toxicity.
Prolanta (100 µg) or docetaxel (25 µg) or the combination were
evaluated in a mouse model of human SKOV3 cell line (above) or mouse ID8
ovarian cancer (below).
Control mice received mannitol buffer (Prolanta vehicle formulation)
only.
Ovarian Cancer
Ovarian Cancer Targeted Therapy
|